Glenmark Pharmaceuticals Ltd – Q1 FY26 Snapshot

1. Business Overview Glenmark is a global research-led pharmaceutical company based in India, with operations spanning generics, branded formulations, specialty drugs, and R&D-driven innovation. 2. Q1 FY26 Key Performance Metrics • Revenue: ₹3,059–₹3,264 crore (flat to slightly down YoY). • EBITDA: ₹580–581 crore; margin at ~17.8%. • Consolidated net profit dropped 86% YoY to ₹47 crore, largely due to a one-time ₹323 crore provision for a US litigation settlement. • Adjusted PAT (excluding exceptional item) stood at ₹313 crore, about 9.6% margin. • Sequential recovery seen in North America (+8.9% QoQ), with India up ~3.7% YoY; Europe slipped ~4%. 3. Geographical Business Trends • India: ₹1,240 crore (↑3.7%). • North America: ₹778 crore (flat YoY, +8.9% sequentially). • Europe: ₹668 crore (↓4%). • Emerging markets: Modest growth around 0–0.2%. 4. Strategic Developments • Expect double-digit Q2 growth in Europe and emerging markets, based on sustained multi-year growth trajectories. • Recently inked a licensing agreement with AbbVie for ISB 2001, reflecting its push into branded and branded innovation. 5. Analyst Viewpoints • Brokerage reports suggest the Q1 decline is temporary. Focus remains on higher-margin segments like injectables, branded therapies, and partnerships. • Motilal Oswal and others maintain 'Buy' ratings, with target prices ranging between ₹2,400–₹2,530. 6. Risks & Considerations • The litigation-related provision weighed heavily on Q1 earnings. • Headwinds in Europe and emerging markets need monitoring. • Valuation multiples may look high without robust recovery; growth is contingent on new product pipelines and market execution. Conclusion Glenmark’s Q1 FY26 performance was a mixed bag: revenues remained flat, margins under pressure, and profits fell sharply due to litigation-related charges. However, underlying business segments like North America and India are showing sequential strength, while the adjusted PAT remains reasonable.